ndonesian government will inject Rp2 trillion (US$142.83 million) to state-owned pharmacy company, PT Bio Farma to construct vaccine manufacturing and production facilities, especially primary medicinal raw materials - Photo by the Company

JAKARTA (TheInsiderStories) – Indonesian government will inject Rp2 trillion (US$142.83 million) to state-owned pharmacy company, PT Bio Farma to construct vaccine manufacturing and production facilities, especially primary medicinal raw materials, said the official last week. The stepped has been taken to reduces import from other country

The director general of at finance ministry, Isa Rachmatarwata, said in a virtual conference, the decision now waiting for the parliament’ approval. In September, President Joko Widodo has announced, the country has allocated Rp40.8 trillion to produces a COVID-19 vaccines in multi-years. For this year alone, President Joko Widodo administration prepared Rp3.8 trillion for the projects.

Coordinating minister for the economic affairs (CMEA), Airlangga Hartarto in a presser on Sept. 8, said the budget will support the Merah Putih vaccine project initiated by the research and technology ministry with the Eijkman Institute, and Indonesian Institute of Science. State-owned pharmacy company, PT Bio Farma joined with China’ drug-maker, Sinovac Biotech, has also prepared 290 million doses of vaccines.

Health ministry will also prepare the operationalization of the vaccination, which is expected to start early in the year. Based on the ministry of health’ report, Indonesia has 196,989 positive cases, after a five-day run of more than 3,000 cases a day since last week. The death toll also jumped to 8,130 with a total of 138,575 recovered cases.

In August, the head of states stated Indonesia could produces the vaccines on the firs semester of 2021. Biofarma, Sinovac and other stakeholders now in the process to creates the new medicines and has been tested for third time, he adds.

“For three months we developed our own vaccine with brand Merah Putih. Its estimated that this can be completed in mid-2021 by various parties and open themselves to collaborating with SINOVAC, Uni Arab Emirates, South Korea and others to be able to vaccinate all Indonesian people,” said Widodo.

On July 21, a total of 2,400 vaccines from Sinovac have arrived at Bio Farma. According to the CEO, Honesti Basyir, the clinical trial of the vaccine is scheduled to run for six months, so it is targeted to be completed in January 2021.

“If the clinical trial of the vaccine phase three goes well, then Bio Farma will produce it in the first quarter of 2021,” he told reporters, by adding the company,have prepared production facilities at Bio Farma with the maximum production capacity is 250 million doses.

Basyir explained, the vaccines that came on last July, still require several more stages and must be passed include testing Biofarma‘ laboratory and several other licenses. This vaccine clinical trial will take as many as 1,620 subjects with an age range between 18 and 59 years and certain criteria.

He said, the reason for choosing Sinovac as a partner caused  the vaccine manufacturing method used same with the company’ current competences. With this inactivation method, the pharmacy firm already has experience in making vaccines such as the Pertussis vaccine.

The remainder of the vaccine will be used for laboratory tests in several laboratories including Bio Farma and the National Food and Drug Testing Center. In the clinical trial of the vaccine, Bio Farma acted as a sponsor, collaborating with various parties, including the Indonesian Health Research and Development Agency of the ministry of health, as medical advisor and implementing neutralization antibody titer tests.

Beside, the producer also collaborates with National Agency of Drug and Food Control as the regulator and of course with the Padjajaran University as an institution that has experience in implementing clinical trials of vaccines circulating in Indonesia.

The development of the vaccine is one of five scenarios for Bio Farma, in dealing with the spread of the SARS COV2 virus, including production of realtime polymerase chain reaction, convalescent plasma therapy, mobile BSL 3 laboratories, and manufacturing viral transport media.

Bio Farma is a state-owned pharmaceutical holding company with subsidiary members, namely PT Kimia Farma Tbk (IDX: KAEF), PT Indofarma Tbk (IDX: INAF), and PT Phapros Tbk (IDX: PEHA).

US$1: Rp14,700

Written by Editorial Staff, Email: theinsiderstories@gmail.com